Health Economics›Rhabdomyosarcoma pediatric›High Risk, all lines of therapy

High Risk, all lines of therapy

Rhabdomyosarcoma pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG D9802 VCPT Alternating with VAC Arm	—	R 72 876	—	—	—	—	—	—
COG D9802 VAC Alone Arm	—	R 49 872	—	—	—	—	—	—

2 of 2 regimens shown